激酶
极光激酶
癌症研究
前列腺癌
极光抑制剂
PTEN公司
生物标志物
癌症
生物
细胞生物学
信号转导
PI3K/AKT/mTOR通路
遗传学
细胞周期
作者
Haoyan Li,Yin Wang,Kevin K. Lin,Varadha Balaji Venkadakrishnan,Mohamadreza K. Bakht,Wei Shi,Chenling Meng,Jie Zhang,Kaitlyn Tremble,Xin Liang,Jian Song,Xu Feng,Vivien Van,Pingna Deng,Jared K. Burks,Ana Aparicio,Khandan Keyomarsi,Junjie Chen,Yue Lu,Himisha Beltran,Di Zhao
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-06-30
卷期号:82 (17): 3088-3101
被引量:2
标识
DOI:10.1158/0008-5472.can-22-0631
摘要
Clinical studies have shown that subsets of patients with cancer achieve a significant benefit from Aurora kinase inhibitors, suggesting an urgent need to identify biomarkers for predicting drug response. Chromodomain helicase DNA binding protein 1 (CHD1) is involved in chromatin remodeling, DNA repair, and transcriptional plasticity. Prior studies have demonstrated that CHD1 has distinct expression patterns in cancers with different molecular features, but its impact on drug responsiveness remains understudied. Here, we show that CHD1 promotes the susceptibility of prostate cancer cells to inhibitors targeting Aurora kinases, while depletion of CHD1 impairs their efficacy in vitro and in vivo. Pan-cancer drug sensitivity analyses revealed that high expression of CHD1 was associated with increased sensitivity to Aurora kinase A (AURKA) inhibitors. Mechanistically, KPNA2 served as a direct target of CHD1 and suppressed the interaction of AURKA with the coactivator TPX2, thereby rendering cancer cells more vulnerable to AURKA inhibitors. Consistent with previous research reporting that loss of PTEN elevates CHD1 levels, studies in a genetically engineered mouse model, patient-derived organoids, and patient samples showed that PTEN defects are associated with a better response to AURKA inhibition in advanced prostate cancer. These observations demonstrate that CHD1 plays an important role in modulating Aurora kinases and drug sensitivities, providing new insights into biomarker-driven therapies targeting Aurora kinases for future clinical studies.CHD1 plays a critical role in controlling AURKA activation and promoting Aurora kinase inhibitor sensitivity, providing a potential clinical biomarker to guide cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI